The failure of an adjuvant trial for the TKI pazopanib was likely caused by a protocol change that reduced the dose to manage transaminitis. While well-intentioned to improve tolerability and adherence, the lower dose was sub-therapeutic. This serves as a critical lesson that managing side effects by compromising dose can nullify a drug's potential efficacy.

With only one-third of pancreatic cancer patients advancing to second-line treatment, oncologists must carefully select first-line therapies. This may involve choosing less toxic combinations to preserve patient fitness for subsequent treatments, like emerging KRAS inhibitors, rather than using the most aggressive option upfront.

To improve long-term tolerability of amivantamab, some experts advocate for a "marathon, not a sprint" approach. This involves aggressive dose holds or reductions at the earliest signs of toxicity, even low-grade, to prevent side effects from escalating and ensure patients can remain on effective therapy longer.

A critical reason patients stop ADC treatments is the burden of side effects like skin toxicity or GI issues, not just disease progression. This underscores the urgent need to develop ADCs with better safety profiles, enabling patients to stay on effective therapy longer.

Beyond rigid trial protocols, a flexible approach to first-line T-DXd is practical and patient-centered. This includes discussing treatment breaks for holidays or switching to a less burdensome maintenance regimen (like subcutaneous HP) if a patient is tired of frequent clinic visits, prioritizing their quality of life.

For patients who achieve a deep response to a PARP inhibitor but struggle with persistent hematologic toxicity despite dose reductions, a practical clinical strategy is to switch to a different agent within the same class (e.g., from olaparib to rucaparib). This may offer a chance for improved tolerability while maintaining therapeutic benefit.

The PR21 trial showed better overall survival for docetaxel followed by Lutetium, despite similar progression-free survival. The likely reason is not drug superiority but patient behavior: a higher percentage of patients complete the second therapy when starting with chemo, highlighting how treatment fatigue significantly impacts survival.

Data on Enfortumab Vedotin suggests that for modern therapies, maintaining patients on treatment longer via a lower, more tolerable starting dose is more important than administering the maximum labeled dose upfront, a concept inherited from the cytotoxic chemotherapy era.

The LIDERA trial showed that while jiridestrant and standard therapies had similar adverse event profiles, patients on jiridestrant had significantly lower discontinuation rates. This highlights that a patient's subjective experience of tolerability is a more critical factor for long-term adherence than a simple list of side effects.